12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oxycodone-naltrexone: Phase III data

Pfizer reported top-line data from the open-label, single-arm, U.S. Phase III Study ALO-02-10-3001 trial in 395 patients with moderate to severe chronic, non-cancer pain showing that the adverse event profile of once- and twice-daily ALO-02 for up to 12 months was as expected based on similar...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >